CRISPR/Cas9 - Mediated Precise Targeted Integration In Vivo Using a Double Cut Donor with Short Homology Arms.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28527830.
- Also identified by DOI 10.1016/j.ebiom.2017.05.015 and PMC identifier 5478232.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Precisely targeted genome editing is highly desired for clinical applications. However, the widely used homology-directed repair (HDR)-based genome editing strategies remain inefficient for certain in vivo applications. We here demonstrate a microhomology-mediated end-joining (MMEJ)-based strategy for precisely targeted gene integration in transfected neurons and hepatocytes in vivo with efficiencies up to 20%, much higher (up to 10 fold) than HDR-based strategy in adult mouse tissues. As a proof of concept of its therapeutic potential, we demonstrate the efficacy of MMEJ-based strategy in correction of Fah mutation and rescue of Fah<sup>-/-</sup> liver failure mice, offering an efficient approach for precisely targeted gene therapies.
Medical subject headings
- CRISPR-Cas Systems
- Gene Targeting
- Recombinational DNA Repair